SuperworthResMed Inc. RMD
Medical - Instruments & Supplies, Healthcare
$225.57
−0.18%
- Market cap
- $32.5B
- PE
- 21.7×
- 10y median 37.3×
- Forward PE
- Price to sales
- 5.8×
- EV/EBIT
- 16.7×
- Revenue, 12 months
- $5.7B
- +10% on a year ago
- Net margin
- 26.9%
- Free cash flow yield
- 5.1%
ResMed trades at 21.7× trailing earnings, cheaper than 96% of the last ten years. Revenue was $5.7B over the last twelve months, up 10% on a year earlier with a 27% net margin.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2B | $1.2B | $1.2B | $1.2B | $1.3B+10% | $1.3B+8% | $1.3B+10% | $1.3B+9% | $1.4B+11% | $1.4B+11% | $1.5B+9% | |
| Cost of revenue | $515.9M | $504.2M | $507.7M | $507.3M | $530.8M+3% | $525.3M+4% | $527.9M+4% | $514.8M+2% | $544.1M+3% | $540.4M+3% | $602.4M+14% |
| Gross profit | $646.9M | $692.8M | $715.5M | $717.2M | $751.3M+16% | $766.4M+11% | $820.1M+15% | $820.8M+14% | $878.7M+17% | $891M+16% | $861.2M+5% |
| R&D | $73.9M | $77.1M | $80.9M | $79.5M | $81.4M+10% | $83.9M+9% | $86.4M+7% | $87.3M+10% | $91M+12% | $94.3M+12% | $105.7M+22% |
| SG&A | $222.2M | $229.9M | $242.2M | $239M | $241.6M+9% | $245.3M+7% | $267.2M+10% | $259.2M+9% | $278.4M+15% | $285.7M+17% | $296.3M+11% |
| $275.1M | $374.6M | $381.2M | $387.3M | $417.2M+52% | $426.3M+14% | $454.5M+19% | $446.5M+15% | $491.7M+18% | $499.8M+17% | $448.7M−1% | |
| Interest expense | $13.8M | $14.4M | $9.6M | $5.5M | $4.8M−65% | $3.2M−78% | $0 | $8.8M+60% | $7.9M+66% | $12.3M+286% | $0 |
| Pre-tax income | $259.5M | $375.4M | $357.7M | $383.5M | $418.3M+61% | $417.7M+11% | $458.1M+28% | $446.8M+17% | $496.1M+19% | $502.3M+20% | $474.2M+4% |
| $50.7M | $74.9M | $65.5M | $72.1M | $73.7M+46% | $52.7M−30% | $78.3M+20% | $98.3M+36% | $103.6M+41% | $103.6M+97% | $90.7M+16% | |
| Net income | $208.8M | $300.5M | $292.2M | $311.4M | $344.6M+65% | $365M+22% | $379.7M+30% | $348.5M+12% | $392.6M+14% | $398.7M+9% | $383.4M+1% |
| $1.42 | $2.04 | $1.98 | $2.11 | $2.34+65% | $2.48+22% | $2.58+30% | $2.37+12% | $2.68+15% | $2.74+11% | $2.64+2% | |
| 147.5M | 147.4M | 147.5M | 147.6M | 147.5M+0% | 147.2M−0% | 147M−0% | 146.9M−1% | 146.4M−1% | 145.7M−1% | 145M−1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Instruments & Supplies within ten times ResMed's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RMDResMed Inc. | $32.6B | 21.7× | 37.3× | 5.8× | +10% | 26.9% | |
| WSTWest Pharmaceutical Services, Inc. | $25.8B | 46.9× | 45.8× | 7.8× | +12% | 17.0% | |
| MDLNMedline Inc. | $46.6B | 41.2× | 32.3× | 1.6× | +15% | — | |
| BDXBecton, Dickinson and Company | $49.1B | 54.3× | 47.3× | 2.4× | −3% | 4.5% | |
| ISRGIntuitive Surgical, Inc. | $146.4B | 47.5× | 69.0× | 13.3× | +21% | 28.4% | |
| Peer median | $47.8B | 47.2× | 46.6× | 5.1× | +14% | 17.0% |
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .